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The Haunting of Medical Literature
Bneann Miller, hfth-year i:tiarmacy student from Fairfield, Ohio, Tana Peterman, fifth-year pharmacy student from Jacksonville, N.C.

Abstract
Ghostwriting, or using the names of academic researchers to
validate studies commissioned by pharmaceutical companies, has
become a growing concern within medical literature. Omission from
authorship of the names of individuals making considerable conllibutions to a paper is one of the most significant aspects of ghostwriting. Policy prohibiting medical ghostwriting is lacking, and it is nearly
impossible to prevent the practice without strict and thorough guidelines. More strict guidelines banning ghostwriting, denying government funds to organ12at1ons without such policies, and development
of databases to track offending authors and organizations could
decrease the impact of ghostwnting in medical literature.
Background
Clinical evidence has come to be revered as the standard of truth in
medical practX:e. Pharmacists turn to clinical literature to make sound
recommendations for patient drug therapy. It 1s often ass urned that
the integrity and validity of a published paper is ensured by referring to
literature in esteemed, peer-reviewed journals. However, ethical considerations and conflicts of int'lrest in authorship are slipping through
quality assurance systems employed by these pumals and threatening
the foundation of medicine. Ghostwriting, or using the names of academrc researchers to validate studies comm1ss1oned by pharmaceuncal
companies, has become a growing concern within medical lrterarure.1
Also concerning may be the use of publication planning, a form of
systematically populating mec1cal literature on the corporate scale.
Publication planning 1s conducted by a team of people employed by a
pharmaceutical manufacturer in an attempt to control every possible
aspect of public information available about a drug of interest.2
PublicatJon plans include strategies for conducting explicit trials that
yield desired results combined with the carefully timed release of
information to specific target audiences. In some cases, the planning
team may be more responsible for manuscripts submitted to medical
pumals than the respected author(s) appearing on the page.
Contributing Factors
The first factor conrributing to medical ghostwriting is the definition of
authorship. The correct protocol for listing authors 1s complicated by
histoncal methods of listing authors alphabetically or l1Sting the head
of department as lead author as a sign of respect.3 Currently, the
International Committee ot Medical Journal Editors defines authorship as fulfilling allot the following criteria for authorship suootantial
contnbutJon to conception anc design , acquisition of data, or analys1S
and 1merpretat10n of data, drafting the article and/or revising 1t cntically
for important intellectual content, and final approval of the version to
be published.• Om1Ssion of the names of ind1v1duals making consider1
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able contributions to a paper from authorship is one of the
most significant aspects of ghostwntmg. More importantly, with
the title of author comes a responsibility to ensure that the
paper's content, intent and findings are based on the results of
the study and scientific principle and not skewed by financial
or political gain.5 Authors list disclosure statements to inform
the reader of existing conflicts of interest; however, the term
"conftlct of interest' 1s difficult to define. These conflicts typically
include employment, grants and other financial support, bur the
lines become blurred when referring to patent nghts. personal relationships or political ties. When the true authors are
excluded from publications, rhey cannot be held responsible tor
the integrity of their work.
Polley proh1b1ting medical ghostwntmg 1s lacking. In an evaluation of 50 of the top academic medical centers m the United
States, 52 percent had no published policy regarding authorship or ghostwritmg.1 Without a policy in pace, It IS nearly
impossible to stop this type of unethical misconduct While the
responsibility of honesty and disclosure lies with the author,
there are few tools available for editors to police authorship validity 5 A mere 8.8 percent of pumals have a policy for verifying
author claims and conflicts of interest.6
A case of Ghostwriting
An example of ghostwriting that is thought to significantly
impact the medical literature was when a oharmaceutJcal
manufacturer attempted to prove that their drug could be used
as an antidepressant in adolescents. 7 This study's results were
published 1n the Journal of the American Academy of Child
and Adolescent Psychiatry and listed 22 authors. The idea for
the study came from the primary author and was accepted and
conducted by the pharmaceutical manufacturer However, the
result of this study and similar studies showed no efficacy for
the drug in adolescents compared to placebo. The manufacturer worried that the lack of efficacy in pediatrics would possibly
make the medical community question the efficacy of the drug
in general. Therefore, the manufacturer decided only to publish
the positive findings from the study. A medical publishing company was hired to draft the positive information and prepare it
for publicat10n.
A synopsis of the clinical report was provided to the ghostwnter
1n the medical publlshing group who used this shortened report
to wnte the first draft of the manuscnpt. The ghostwnter also
was found to have contributed to the article by developing and
implementing a publication plan, responding to peer-reviews,
and providing the primary author with drafts and cover letters.
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Research looking into the communication between the listed authors and
employees at the medical publishing company showed that many of the
22 listed authors had little to no involvement with the article. The ghostwnter was actually the pnmary writer of the article drafts, even though
not listed as such. Also, 1t was shown that the second and third authors
made only minor edits to the articlg throughout the process. Many of the
authors were shown to have only made small edits to one of the drans.
having only assisted in running the study, or having made no recognizable contribution at all. 7
A mapr issue with the first draft was that there were noticeable differences between it and the final clinical report, even though this was
the source used to write the first draft. In the clinical report it is stated
that only two primary outcomes were measured. In the first draft, eight
primary outcomes were mentioned: four of these outcomes showed
increased efficacy of the drug over placebo, which contradicts the
findings of the srudy. Also, the line between the primary and secondary
outcomes was blurred. After peer review, the article was edited again to
include only the original two pnmary outcomes , but the information was
presented in such a way that one of the outcomes appeared to be pos1t1ve and reinforced the Idea of efficacy for the drug. The side effects of
the medication were inconsistent with the original report as well, and the
seriousness of some listed side effects was not expressed. 7
The results of this study being published include many clinicians
believing the drug to be an effective and highly tolerable medication
for adolescents. In 207 articles published since 2008, this study was
mentioned and used as evidence that the drug is effective for use in
adolescents. Only 31 of these articles correctly presented the information from the onginal study and showed slight skepticism over the results
of thA puhlication.1
Possible Solutions
Strict defintt10ns of authorship need to be included in the policies of
both medical pumals and academic medical centers. It 1s not enough
to condemn ghostwn!lng; the term needs to be extensively defined to
be enforceable.' ThlS strategy can further be amplified by government
funding denying grants to 1nst1tut1ons that lack these stringent ethical
policies. Enforcement of these policies could be further reinforced by
purnals requiring listed article aut1ors to sign a statement guaranteeing
the integrity of their article and holding them accountable if dishonesty
is suspected.aIf violation of these policies is proven, offenders could be
punished by revoking government funding, refusing to publish subsequent works by the author, and enforcing legal responsibility for falsifying
documents.' These exclusions could be made possible by compiling
an online database for easy access to a list of an author or institution's
ethical infractions.3
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Discussion
Ghostwriting will not be stopped until all levels of medical publishing
commit to higher standards for literary ethics. PractitJoners have a right
to be informed of these conflicts of interest in literature so they can
make their own decisions about the clinical validity of the evidence they
are reading. Ghostwriting and publication planmng allow publication of
biased or incomplete 1ntormat1on that may be harmful to patients who
begin therapy with a medication with side effects and risks that are not
fully disclosed. Many patients now may be suffering from severe adverse
effects of medications because the dangers were not known and the
treatment was marketed as being safe and effective. Ghostwriting is an
emerging problem in medical writing that not only has ethical implications, but also affects patients and their wellbeing. The quality of medical
care provided to patients is only as strong as the integrity of the literature
that backs it.
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